Loss of p53-inducible long non-coding RNA LINC01021 increases chemosensitivity

Markus Kaller,Ursula Götz,Heiko Hermeking

DOI: https://doi.org/10.18632/oncotarget.22245

2017-11-01

Oncotarget

Abstract:We have previously identified the long non-coding RNA <i>LINC01021</i> as a direct p53 target (Hünten et al. Mol Cell Proteomics. 2015; 14:2609-2629). Here, we show that <i>LINC01021</i> is up-regulated in colorectal cancer (CRC) cell lines upon various p53-activating treatments. The <i>LINC01021</i> promoter and the p53 binding site lie within a MER61C LTR, which originated from insertion of endogenous retrovirus 1 (ERV1) sequences. Deletion of this MER61C element by a CRISPR/Cas9 approach, as well as siRNA-mediated knockdown of <i>LINC01021</i> RNA significantly enhanced the sensitivity of the CRC cell line HCT116 towards the chemotherapeutic drugs doxorubicin and 5-FU, suggesting that <i>LINC01021</i> is an integral part of the p53-mediated response to DNA damage. Inactivation of <i>LINC01021</i> and also its ectopic expression did not affect p53 protein expression and transcriptional activity, implying that <i>LINC01021</i> does not feedback to p53. Furthermore, in CRC patient samples <i>LINC01021</i> expression positively correlated with a wild-type p53-associated gene expression signature. <i>LINC01021</i> expression was increased in primary colorectal tumors and displayed a bimodal distribution that was particularly pronounced in the mesenchymal CMS4 consensus molecular subtype of CRCs. CMS4 tumors with low <i>LINC01021</i> expression were associated with poor patient survival. Our results suggest that the genomic redistribution of ERV1-derived p53 response elements and generation of novel p53-inducible lncRNA-encoding genes was selected for during primate evolution as integral part of the cellular response to various forms of genotoxic stress.